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Introduction
Biliary tract cancers (BTC) comprise a heterogeneous 
group of malignancies arising along the biliary tree 
with a low incidence and poor prognosis. BTC account 
for nearly 3% of all gastrointestinal cancers (1) and are 
classified according to anatomical location into intrahepatic 
cholangiocarcinoma (iCCA), perihilar cholangiocarcinoma, 
also known as Klatskin tumor (pCCA) and distal 
extrahepatic cholangiocarcinoma (eCCA). Despite having a 
different biological behavior and prognosis, ampullary and 
gallbladder cancers are grouped with cholangiocarcinoma 
(CCA) in some series.
Radical surgery is the only available treatment with 
curative intent. Five-year survival rates range from 20% 
to 32% for iCCA, 30% to 42% for pCCA and from 18% 
to 54% for eCCA (2). Unfortunately, only a minority of 
patients (20–30%) are diagnosed with early resectable 
disease and the rate of recurrence is high (2). In addition, 
the effectiveness and modalities of laboratory/instrumental 
follow-up after surgery remain unclear.
Some  se r i e s  e xp lo red  the  f e a s ib i l i t y  o f  l i v e r 
transplantation (LT) on early iCCA and pCCA (in the latter 
case after neoadjuvant radiochemotherapy). Overall LT is 
not readily available and its effectiveness, especially in iCCA 
patients, remains controversial (3,4).
The rationale for adjuvant treatment after surgery is 
to reduce the risk of relapse and improve the long-term 
outcome of resected patients. However, few high quality data 
on adjuvant treatments in BTC patients have been published 
to date. A combination of cisplatin and gemcitabine is the 
standard first-line chemotherapy (CTX) regimen in patients 
with advanced BTC. No standard second-line treatment has 
been established to date. Several clinical trials of therapies 
targeted against new actionable mutations (such as IDH1/
IDH2 mutations and FGFR-2 fusion proteins) are now 
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ongoing (5). This paper summarizes the available data and 
clinical evidence, and discusses the main open questions on 
adjuvant strategies in resected BTC patients.
Prognostic factors after surgery
Considering that less than one third of patients with CCA 
undergo a potentially curative resection and the disease has 
a high relapse rate, the identification of negative prognostic 
factors may serve to select a group of patients who could 
benefit most from adjuvant treatments.
The overall survival (OS) of patients who undergo 
surgical resection with curative intent varies according 
to pathological stage (6). A recent retrospective multi-
institutional analysis evaluated the prognostic accuracy of 
the latest AJCC staging system (7) in patients with iCCA, 
showing that 5-year OS for patients classified as stages 
Ia, Ib, II, IIIa and IIIb was 90.0%, 50.6%, 55.1%, 49.7% 
and 16.2%, respectively (8). According to the results of a 
retrospective analysis of surgical series, the main prognostic 
factors associated with survival and risk of relapse in resected 
CCA patients are lymph node involvement and histologic 
margin status for both intrahepatic and extrahepatic 
forms. DeOliveira and colleagues’ retrospective mono-
institutional series found surgical margin status (P<0.001), 
lymph node status (P<0.001) and tumor differentiation 
(P<0.001) independent prognostic factors at both univariate 
and multivariate analysis. Moreover, among R0-resected 
patients, only nodal status was significantly associated with 
survival (HR 1.73, 95% CI: 1.26–2.39; P<0.001) (9).
The role of lymphadenectomy in the surgical treatment 
of iCCA is controversial. Uchiyama et al. reported that 
pathological lymph node involvement was significantly 
associated with poor survival (HR 2.10, P<0.001) in patients 
treated with radical resection for iCCA, while a high 
preoperative CA 19.9 (>135 U/mL) was the only significant 
factor predicting the risk of nodal involvement (10). A 
retrospective multicenter Italian study on 430 patients 
who underwent potentially curative resection for iCCA 
showed that lymph node metastasis was the most relevant 
independent predictor of poor survival (HR 2.21, 95% CI: 
1.55–3.15; P=0.005), followed by elevated preoperative 
CA 19-9 levels (HR 1.62, P=0.006) and multiple tumors 
(HR 1.50, P<0.001) (11). Several studies showed that the 
ratio between the number of positive lymph nodes and the 
number of total lymph nodes examined is an independent 
prognostic factor for both OS and recurrence-free survival 
(RFS) in resected BTC (12). In de Jong et al.’s series of 449 
patients with resected iCCA, vascular invasion and multiple 
tumors were significantly associated with poor prognosis. 
Lymph node involvement (N1) in the subgroup of patients 
who received lymphadenectomy (n=248) was associated 
with worse survival than node-negative (N0) status 
(mOS 22.9 vs. 30.1 months, respectively, P=0.03) (13). 
Moreover, tumor number and vascular invasion significantly 
influenced prognosis only in N0-patients (P=0.004 and 
P=0.009, respectively), whereas these factors did not affect 
the survival of patients with node-positive disease (P=0.45 
and P=0.30, respectively) (13).
Together with lymph node status, the other main factor 
most influencing the outcome of patients treated with 
radical-intent surgery for BTC is the histologic margin 
status. A French multicenter study on 212 patients treated 
with potentially curative resection for iCCA showed that 
a positive surgical margin at microscopic pathological 
examination (R1) was significantly associated with lower 
survival only among patients without lymph node metastases 
(N0). In the group of N+ patients, OS after R1 and R0 
resection was similar (14). A retrospective analysis of patients 
with pCCA treated at Memorial Sloan-Kettering Cancer 
Center over a nine-year period revealed that survival after R0 
resections was significantly longer than after R1 resections 
(42 vs. 21 months; P<0.008) (15). Uchiyama et al. showed that 
positive resection margins significantly reduced OS (HR 1.81; 
P<0.006) at multivariate analysis in patients with iCCA who 
underwent surgical resection with curative intent (10).
For perihilar BTC, an aggressive surgical approach with 
the addition of a major hepatectomy and a complete caudate 
lobectomy to bile duct resection has improved resectability 
rates in recent years (16). A multicenter Italian study on 
440 consecutive patients with resected pCCA showed that 
aggressive surgical treatment significantly increased median 
OS without a concomitant increase in perioperative mortality. 
Lymph node metastases, R1 resection and T stage ≥3 were 
independent prognostic factors for OS and disease-free survival 
(DFS) at multivariate analysis (17). The prognostic role of 
other factors such as histological subtype, vascular invasion or 
preoperative CA 19-9 levels in patients with resected CCA has 
been studied but their importance in predicting survival and 
risk of recurrence is controversial (2,9,18).
In recent years, some authors have proposed different 
prognostic nomograms to better predict survival after 
potentially curative surgery. For instance, a prognostic 
model based on nodal involvement, tumor differentiation, 
and margin status in resected pCCA patients was proposed 
by Groot Koerkamp et al. (19). Furthermore, the prognostic 
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nomogram for resectable iCCA proposed by Wang et al. 
included lymph node status, vascular invasion, tumor 
diameter and number and serum CEA and CA 19-9 levels, 
proving more accurate in predicting survival compared to 
traditional staging systems. Further studies are required for 
their validation (20).
Adjuvant treatments
Five-year OS after surgical resection does not exceed 40% 
in the best surgical series. Disease relapse occurs mainly 
during the first 2 years. Improving the outcome of surgery 
with adjuvant medical strategies is a major goal, not fully 
achieved to date. Attempts to solve this issue have to tackle 
considerable problems. Firstly, BTC is rare and few patients 
undergo surgery. Hence, it is arduous to design and finalize 
a randomized adjuvant trial with adequate statistical power. 
Secondly, BTC is a heterogeneous disease harboring 
different molecular and biological features (21). Finally, 
until some years ago there was no worldwide consensus 
on the standard CTX regimen also in a metastatic setting. 
Consequently, many adjuvant treatments and regimens have 
been explored in small uncontrolled mono-institutional 
series without a solid background in advanced disease. 
Despite the lack of strong definitive agreement, adjuvant 
CTX is widely employed at least in referral centers. Its use 
in clinical practice is suggested by guidelines and consensus 
statements, especially for patients with node-positive or 
margin-positive disease.
Hereafter, the main published or ongoing studies 
focused on adjuvant CTX, radiotherapy (RT) and 
chemoradiotherapy are reported.
Chemotherapy
Data are available from four prospective trials.
ESPAC-3
This was a three-arm international randomized trial 
in patients with resected periampullary malignancies 
(297 ampullary, 96 bile duct, 35 other). Overall, 428 patients 
were enlisted and randomized to observation (145 pts), 
6 months of leucovorin-modulated 5-fluorouracil (FU) 
(143 pts) or six months of single-agent gemcitabine 
(146 pts). The primary end-point was OS in the treatment 
group compared to the observation group. Secondary end-
points were disease-free survival, toxicities and quality of 
life. Adjuvant CTX provided a potential OS benefit even 
if it was not statistically significant (mOS 43 vs. 35 mo, 
HR 0.86, 95% CI: 0.66–1.11). A pre-planned subset analysis 
of BTC patients (96 pts) reported a mOS of 27, 18, and 
20 months in observation, FU/leucovorin and gemcitabine, 
respectively. Near to 20% of patients in the 5-FU arm did 
not start the therapy and only 49% of them completed all 
pre-planned cycles. Likewise, in the gemcitabine arm, 11% 
of patients did not start the therapy and only 50% of them 
completed all the planned cycles (22).
JSGSAT study
This Japanese study enrolled 508 patients (between 1986 
and 1992) with resected pancreatic (n=173), bile duct 
(n=139), gallbladder (n=140), or ampulla of Vater (n=56) 
cancers. Patients were randomly assigned to adjuvant 
CTX (mitomycin and 5-FU) or observation alone until 
disease recurrence. The treatment started on the day of 
surgery and ended once the patient developed recurrence. 
The treatment completion rate was high (>80%). No 
significant differences in 5-year OS or 5-year DFS rates 
were reported between patients with pancreatic, bile duct, 
or ampulla of Vater cancers. Multivariate analyses showed a 
non-significant lower risk of mortality (risk ratio of 0.654; 
P=0.0825) and recurrence (risk ratio of 0.626; P=0.0589) 
in the CTX group. Adjuvant CTX improved the five-
year OS (26% vs. 14.4%, P=0.03) and DFS (20.3% vs. 
11.6%, P=0.02) in the gallbladder subgroup with respect 
to observation alone, but only in the cases of non-curative 
resection. There are no definitive explanations for the 
reported differences (23). 
PRODIGE 12-ACCORD 18
This French study, presented at the ASCO Gastrointestinal 
Cancers Symposium 2017, is a randomized study that 
compared an adjuvant treatment based on GEMOX to 
surgery alone in 193 patients who underwent R0 or R1 
resections for BTC (24). A pathological involvement of the 
regional lymph nodes (pN1) was reported in about a third 
of cases and microscopic residual disease (R1) in about 13% 
of patients. At a median follow-up of 44.3 months, there 
were no significant differences in terms of RFS between 
the two arms (mRFS 30.4 months for the CTX arm vs. 
22.0 months for the control arm, HR 0.83, 95% CI: 0.58–1.19; 
P=0.31) (24). Final RFS and first OS analysis, presented at 
ESMO 2017 Congress, confirmed the lack of benefit (25).
BILCAP
This was a randomized multicenter phase III trial from the 
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UK evaluating the role of adjuvant CTX with capecitabine 
following potentially curative resection of CCA. The 
study randomized 447 patients with completely resected 
CCA or gallbladder cancer to either adjuvant CTX with 
capecitabine (1,250 mg/mq D1–D14 every 21 days, for 
8 cycles) or observation. The preliminary results of the 
study were presented at the 2017 ASCO Annual Meeting. 
According to the intention-to-treat analysis, median OS was 
36.4 months in the group of patients treated with 
surgery alone and 51.1 months in the adjuvant CTX arm 
(HR 0.81, 95% CI: 0.63–1.04) although the difference was 
not statistically significant (P=0.097). By per-protocol analysis 
on 430 patients, excluding those who stopped capecitabine 
early, adjuvant CTX significantly improved survival compared 
to surgery alone (mOS 53 vs. 36 months, respectively; 
HR 0.75, P=0.028). In addition, sensitivity analyses with 
adjustment for clinical and pathological parameters such as 
nodal status, tumor grade, and gender showed a significant 
survival benefit in favor of capecitabine (HR 0.70, 95% CI: 
0.55–0.91; P=0.007) (26). Based on these results, CTX with 
capecitabine will potentially become the new standard of care 
for adjuvant treatment in patients with BTC.
Radiotherapy and chemoradiotherapy
The role of adjuvant RT alone was evaluated in only 
one prospective, no-randomized trial at Johns Hopkins 
Hospital from 1988 to 1993 (27). Pitt et al. enlisted 50 non-
metastatic CCA patients who underwent radical and non-
radical resections or palliative surgery. Patients were treated 
or not with RT and stratified by tumor resection and other 
parameters that might have affected their outcome. RT did 
not improve survival either in resectable or in unresectable 
patients.
The role of adjuvant chemoradiotherapy was assessed by 
the studies summarized below.
EORTC
This was a small two-arm randomized trial which included 
207 patients with pancreatic or periampullary malignancies 
(75–80% of R0 resection). A postoperative fluoropyrimidine-
based chemoradiotherapy (total absorbed dose of 40 Gy 
and concomitant radio-sensitizing 5-FU) was compared to 
surgery alone. Patients enrolled in the combination arm 
were treated for a total of six weeks, including the two 
weeks of rest between the first and the second course of 
chemoradiotherapy. The trial failed to show a benefit in OS 
or progression-free survival, but fewer than 100 patients 
had periampullary malignancies and even fewer distal BTC. 
Furthermore, the dropout rate in the treatment arm was 
20% due to postoperative complications or refusal.
SWOG S0809
The SWOG S0809 was a single arm prospective phase 
II trial of adjuvant combination CTX (capecitabine plus 
gemcitabine) followed by RT and concurrent capecitabine 
in eCCA and gallbladder cancer. Overall treatment lasted 
from 18 to 19 weeks. Patients received four cycles of CTX 
(12 weeks) and five to six weeks of chemoradiotherapy 
(starting in the thirteenth week). Seventy-nine eligible 
patients were treated. Eligibility criteria were pT2-T4 
disease, node-positive disease or R1 resection. Two-year 
OS and DFS were 65% and 52%, respectively. Median OS 
was 35 months. No significant differences were observed 
between R0 and R1 patients (28).
Meta-analysis and main retrospectives series on 
chemotherapy 
In 2010, Horgan et al. published a large meta-analysis 
evaluating 6,712 BTC patients (1,797 pts were treated 
with adjuvant treatment) enrolled in single randomized 
trials of CTX alone in two SEER registry analyses and in 
17 retrospective institutional series (29). Eligible studies 
included patients with eCCA, iCCA and gallbladder 
cancers who underwent curative resection [negative (R0) or 
microscopically positive (R1) margins] as a control group. 
Nine of the studies were on RT alone, three on CTX 
alone, and eight on RT-CTX combinations. Only one 
study was focused on patients with iCC. Compared with 
surgery alone, adjuvant treatment produced no statistically 
significant improvement in five-year survival [pooled odds 
ratio (OR) 0.74, 95% CI: 0.55–1.01]. Separate analysis of 
gallbladder and bile duct cancers yielded similar results. 
Survival benefit was statistically significant when data from 
the two large registry series (1,233 patients) were excluded 
(OR 0.53, 95% CI: 0.39–0.72). Concerning gallbladder and 
bile duct cancers there was a significant survival benefit for 
CTX (OR 0.39, 95% CI: 0.23–0.66) and chemoradiotherapy 
(OR 0.61, 95% CI: 0.38–0.99) but not for RT alone 
(OR 0.98, 95% CI: 0.67–1.43). A statistically significant OS 
advantage was reported for adjuvant CTX (77% of patients) 
or chemoradiotherapy in node-positive patients (OR 0.49, 
95% CI: 0.30–0.80) analyzing pooled data from nine studies 
which included at least half of the patients with confirmed 
nodal or marginal disease. Likewise, patients with margin-
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positive disease seemed to benefit from adjuvant therapy 
(OR 0.36, 95% CI: 0.19–0.68). Nearly two-thirds of them 
(63%) had received RT alone. Conversely the majority of 
studies with R0-resection patients used chemoradiotherapy 
and most included node-positive patients. For patients 
without nodal involvement, data were limited and not 
sufficient to reach definitive conclusions on the benefits 
of adjuvant therapies. In conclusion, Horgan et al.’s meta-
analysis seems to support current practice even if it does not 
pinpoint the best treatment strategy for high-risk patients 
(i.e., node-positive or marginal disease) nor does it quantify 
the benefit of adjuvant therapy for patients with low-risk 
disease. Furthermore, it has some limitations. Firstly the 
bibliographic search was restricted to studies published 
in English. Secondly, the authors did not assess the 
heterogeneity of the studies in individual analyses. Lastly, 
only a few demographic details of the patients included 
were reported.
A first retrospective series included 263 Thai patients who 
underwent radical resection for CCA between 2009 and 2011. 
One hundred and thirty-eight received adjuvant CTX while 
the remaining 125 underwent observation. Various CTX 
regimens were included, both single agents (gemcitabine, 
5-FU or capecitabine) or combination regimens (such as 
gemcitabine/capecitabine or 5-FU/mitomycin C). The CTX 
group included younger patients than the control group. 
Furthermore patients in the CTX group had a better liver 
function and/or post-surgery recovery (nutritional status) 
since their albumin levels were higher. The OS was longer in 
the CTX group than in the observation cohort (21.6 vs. 13.4 
months, P=0.01). Patients who received adjuvant treatment 
were 35% less likely to die at any time earlier than those who 
did not (HR 0.65; 95% CI: 0.47–0.91). High-risk disease 
features (such as high level of CA 19-9, advanced stage, nodal 
involvement and marginal resection) seemed to be related to 
a greater benefit of CTX (30).
The effectiveness of adjuvant CTX with gemcitabine 
and S-1 was retrospectively evaluated in another Japanese 
case series. S-1 is an oral anticancer drug combining 
three compounds, namely tegafur, gimeracil and oteracil 
potassium. One hundred and three patients with UICC 
IIA-IIB stage BTC and R0/R1 resection were included: 
50 were treated with adjuvant CTX while 53 had 
observation alone. Five-year OS rates were 57% and 
24%, respectively. Statistical significance was reached in 
both R0 and R1 patient subgroups (P=0.022 and P=0.012, 
respectively). Conversely, a survival benefit was only 
detected in the node-positive patient subgroup (P=0.006), 
but not in the node-negative patients (P= 0.213) (31).
Meta-analysis on radiotherapy and 
chemoradiotherapy
Two meta-analyses summarized the available evidence on 
adjuvant RT: the first focused on eCCA, the second on 
iCCA. Bonet Beltrán et al. included 858 patients enlisted 
in 13 cohort studies (from 1995 to 2008) (32). Overall, 
400 patients were treated with adjuvant RT and 458 with 
surgery alone. Pooled HR for OS was equal to 0.72 (95% 
CI 0.53–0.98, P=0.037) in favor of the addition of RT. 
A high statistical heterogeneity (I2 index =49.3%) was 
reported due to the imbalanced tumor origin. Focusing on 
eCCA alone, the pooled HR was 0.62 (95% IC 0.48–0.78, 
P<0.001) in favor of RT, with low heterogeneity (I2 index 
=4% and a non-significant Cochran’s Q test). However, 
this study presents some limitations. Firstly, all the studies 
included were retrospective. The number of patients in 
each cohort was small (on average 58 patients) and the 
impact of concurrent systemic CTX is unknown due to the 
lack of individual data. Finally the patients included in the 
RT groups more often had adverse features (e.g., positive 
surgical margins and/or metastatic lymph nodes) (32).
Shinohara et al. conducted a SEER database pooled 
analysis between 1988 and 2003 (33). They included 3,839 
iCCA patients in four distinct treatment groups: surgery and 
adjuvant RT (286 pts), surgery alone (948 pts), RT alone 
(396 pts) and no treatment (2,209 pts). Surgery plus RT was 
associated with an improvement in median OS compared 
to surgery alone (11 vs. 6 months P<0.0138) and a reduced 
hazard ratio of death (HR 0.78, 95% CI: 0.67–0.92) both at 
univariate and multivariate analysis. The authors concluded 
that adjuvant RT could extend survival. The potential 
limitations of this study are: missing data regarding the type 
of surgery and N stage; missing data on T stage for near 
70% of cases; lack of selection criteria for adjuvant RT; 
poor depiction of RT modality (e.g., irradiation technique, 
field covered, total dose delivered, fractions and length of 
treatment, rate of treatment completion, toxicities). Overall, 
the authors concluded that adjuvant RT could extend survival 
even if the evidence provided by their work is poor (33).
Ongoing trials
To date, the only randomized ongoing trial of adjuvant CTX 
in BTC is the ACTICCA-1 study. This is a large multinational 
phase III trial (NCT02170090) currently recruiting patients 
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with resected BTC and randomly assigning them to adjuvant 
CTX with cisplatin and gemcitabine or observation. The 
primary endpoint is DFS (34).
Predictive factors of response
In order to optimize the clinical benefit of an adjuvant 
treatment after surgical resection for BTC, potential 
predictive factors of response need to be identified.
Intracellular uptake of gemcitabine is mediated by a 
specialized membrane nucleoside transporter, namely 
human equilibrative nucleoside transporter 1 (hENT-1) (35). 
Based on the results of retrospective studies in patients with 
locally advanced or metastatic CCA (35) and pancreatic 
cancer, treated with gemcitabine-based CTX, our group 
examined the putative role of hENT-1 as a predictive 
factor in patients who received adjuvant gemcitabine after 
surgical resection for CCA (36). Seventy-one CC tissue 
samples were retrospectively analyzed for hENT1 tumor 
cell localization: 23 (32.4%) cases were completely negative 
for the transporter, 22 (31.0%) showed only cytoplasm 
positivity, and 26 (36.6%) had concomitant membrane/
cytoplasm immunoreactivity. After pooling hENT-1-
negative patients and those positive for hENT-1 in only 
the cytoplasm of tumor cells, survival analysis showed that 
membrane-positive hENT-1 was associated with a longer 
DFS (HR 0.49, 95% CI: 0.24–0.99) than membrane-
negative hENT-1 (36).
A retrospective study by Kobayashi et al. analyzed a series 
of 105 patients with BTC who underwent curative resection 
and then received adjuvant CTX with gemcitabine alone 
or in association with S-1. Fifty-four patients underwent 
observation alone. In the subgroup of 51 patients treated 
with adjuvant gemcitabine-based CTX, hENT1 expression 
was the only independent predictive factor for OS at 
multivariate analysis (HR 2.77, P=0.027) (37). Given the 
retrospective design of these studies and the different CTX 
regimens employed, future prospective clinical trials on 
larger populations are required to confirm the potential 
interaction between hENT-1 localization and the outcome 
of CCA patients receiving adjuvant gemcitabine.
Other potential biomarkers for gemcitabine response 
include the activities of cytidine deaminase (CDA), 
deoxycytidine kinase, and ribonucleotide reductase M1. 
Yoon and colleagues examined whether single nucleotide 
polymorphisms (SNPs) in encoding genes involved in the 
transport and metabolism of gemcitabine were associated 
with its efficacy in treating BTC. A retrospective analysis of 
80 patients with advanced BTC treated with gemcitabine plus 
cisplatin found that an SNP in the CDA (cytidine deaminase) 
gene (CDA 435 C>T polymorphism) was significantly 
associated with tumor response (OR 0.23, 95% CI: 0.06–0.93, 
P=0.039), suggesting a putative role of CDA activity in 
predicting the efficacy of gemcitabine-based CTX (38).
Unsolved questions
The main open questions are: the timing of treatment, the 
dose of RT, and effectiveness and safety in the elderly.
Timing of treatment
This is often based on empirical data. Therapy usually starts 
within two months after surgery and lasts for 6 months. No 
study has specifically addressed this issue or the optimal 
length of therapies. Moreover these parameters vary widely 
among the studies described above.
Dose of radiotherapy
There is a great heterogeneity among the RT studies. The 
total RT dose differs (ranging from 40 to 50 Gy) as does the 
regimen (normal vs. split course). Sometimes a combination 
with boosts (brachytherapy or intra-operative RT) is pre-
planned (this translates into different lengths of treatment). 
The duration of concurrent chemoradiation also differs 
among the studies and in general depends on the RT protocol. 
Elderly patients
Given their retrospective design, the vast majority of studies 
had no clear cut-off for age. Most patients were treated 
according to the risk of relapse and performance status. 
Among the few randomized trials available, the majority 
allowed inclusion unrestricted by age (22,26,28). The Japanese 
trial did not enroll patients older than 75 years (23). The two 
large meta-analyses by Horgan et al. and Bonet Beltrán et al. 
do not provide details on the age of patients treated with CTX 
alone, RT alone or a combination (32). On the basis of the 
available data, we could only assess the adjuvant treatment for 
elderly patients as feasible. Further investigations are required 
to fully understand its effectiveness.
Conclusions
Adjuvant treatments such as CTX, RT or chemoradiotherapy 
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are widely employed in BTC, even if they have mainly 
been explored in small retrospective series until recently. 
Available data and meta-analyses suggest that adjuvant 
strategies, especially CTX, could reduce the risk of relapse 
and potentially improve OS. Subgroups of high-risk patients 
such as those with microscopically non-radical resection or 
with nodal involvement seem to benefit most from adjuvant 
CTX and/or RT. Some retrospective studies investigated the 
putative role of hENT1 expression and cytidine deaminase 
polymorphisms as predictive factors of the effectiveness of 
gemcitabine-based CTX. To date, 5-FU (and prodrugs) or 
gemcitabine have been the mainstay of adjuvant strategies 
for BTC. After the recent results of the BILCAP trial, 
capecitabine has emerged as a referral drug in this setting. 
Specific issues on the length and timing of treatment, 
feasibility in the elderly, RT modalities and the efficacy of 
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